Sign in
Taking peoplePhase 2

Total Neoadjuvant Immunotherapy Plus Chemotherapy for Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Key facts

Who runs it
Beijing Tsinghua Chang Gung Hospital
Where
China2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
42 people, planned
Started
5 Aug 2026
Expected to end
30 Dec 2028
Type of study
Interventional
Treatments tested
  • Serplulimab
  • SOX regimen
Record updated
12 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 30 criteriaShow less

Who can take part

  • Able to understand the study and provide signed informed consent (ICF)
  • Histologically confirmed adenocarcinoma of the stomach or gastroesophageal junction, clinically staged as stage II/III disease (cT1-2N+M0 or cT3-4aNxM0) based on contrast-enhanced CT/MRI
  • Willing to provide archived tumor tissue or undergo biopsy for central laboratory testing of PD-L1, EBV, and MSI/dMMR status
  • Tumor with PD-L1 CPS >=5, or MSI-H/dMMR, or EBV positivity
  • Male or female, age >=18 years
  • ECOG performance status 0-1, with no surgical contraindications
  • Life expectancy >=6 months
  • Laboratory values within 7 days prior to enrollment: absolute neutrophil count (ANC) >=1.5 x 10\^9/L; platelet count >=100 x 10\^9/L; hemoglobin >=90 g/L; serum albumin >=30 g/L; total bilirubin <=1.5 x ULN; AST and ALT <=2.5 x ULN (<=5 x ULN in subjects with liver metastases); creatinine <=1.5 x ULN or creatinine clearance >=50 mL/min; INR and aPTT <=1.5 x ULN (applicable only to subjects not receiving anticoagulant therapy; subjects receiving anticoagulants must be on a stable dose)
  • Good compliance and willingness to cooperate with protocol-required examinations and specimen collection (tissue, blood, stool, and saliva samples)
  • Women of childbearing potential must agree to use contraception from the time of ICF signing until at least 5 months after the last dose of study treatment or accompanying chemotherapy, and must not breastfeed; men must agree to use contraception from the first dose of study drug until at least 7 months after the last dose

Who cannot take part

  • Prior or concurrent other malignancy (except adequately treated basal cell carcinoma of the skin or carcinoma in situ of the uterine cervix)
  • Uncontrolled pericardial effusion, pleural effusion, ascites, or gastrointestinal bleeding within 2 weeks prior to enrollment
  • Body weight loss >20% within 2 weeks prior to enrollment
  • Unable to take oral medications
  • Prior chemotherapy, radiotherapy, targeted therapy, immunotherapy, or surgery for gastric cancer
  • Prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibodies
  • Comorbidities requiring long-term immunosuppressive therapy, or systemic or local corticosteroids at immunosuppressive doses
  • Vaccination with any anti-infectious vaccine within 4 weeks prior to enrollment
  • Currently receiving or requiring anticoagulant therapy (low-dose aspirin antiplatelet therapy allowed)
  • Active tuberculosis, currently receiving anti-tuberculosis treatment, or anti-tuberculosis treatment within 1 year prior to screening
  • Uncontrolled diabetes mellitus, hypertension, or other systemic diseases
  • Any active autoimmune disease or history of autoimmune disease
  • Confirmed interstitial pneumonitis, non-infectious pneumonitis, pulmonary fibrosis, or history of acute lung disease
  • Active hepatitis (HBV DNA >=10\^4 copies/mL or positive HCV RNA)
  • Positive HIV antibody or human T-lymphotropic virus type 1 (HTLV-1) antibody
  • Any other clinically significant disease or condition that, in the investigator's judgment, may affect protocol compliance or render the subject unsuitable for participation
  • Known allergy to serplulimab or its excipients, oxaliplatin, or components of tegafur/gimeracil/oteracil potassium (S-1)
  • HER2-positive tumor confirmed by central laboratory testing (IHC 3+, or IHC 2+ with positive FISH/ISH)
  • Any contraindication to oxaliplatin or S-1
  • Pregnant or breastfeeding women

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study is for people with locally advanced adenocarcinoma of the stomach or of the junction between the stomach and esophagus (gastroesophageal junction adenocarcinoma) that can be removed by surgery. Serplulimab (an anti-PD-1 antibody) has been approved in China for use around the time of surgery in this type of cancer. This study will evaluate a treatment approach called total neoadjuvant therapy, in which all planned immunotherapy plus chemotherapy is given before surgery.

Read full original descriptionShow less

About 42 patients will take part at 2 hospitals in China. All participants will receive serplulimab plus the SOX regimen (oxaliplatin and S-1) before surgery, followed by surgical removal of the tumor. All treatment is given before surgery. After surgery, participants will not receive additional chemotherapy or immunotherapy. They will be followed regularly with examinations and tests to check for any return of the cancer.

Researchers will collect tumor tissue, blood, and stool samples before, during, and after treatment. These samples will be used to study how the tumor and the immune system change during treatment, including the immune cells inside the tumor, the tumor's genetic features, and traces of tumor DNA in the blood. Researchers will also grow mini-tumors (organoids) from patients' tumor tissue in the laboratory to test how the tumor responds to drugs.

The study will measure how completely the tumor shrinks or disappears after treatment, the side effects participants experience, and how long participants remain free of cancer after surgery. Participants will be followed regularly after treatment ends.

The group in the trial

  • Serplulimab + SOXTreatment being tested

    All participants receive total neoadjuvant therapy consisting of serplulimab plus the SOX regimen administered entirely before surgery, followed by radical gastrectomy. No postoperative systemic therapy is administered.

    Treatment: Serplulimab and SOX regimen

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter, Prospective Study of Total Neoadjuvant Immunotherapy Combined With Chemotherapy in Patients With Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: The TNICE-1 Study
Record updated
12 November 2026